CurrentCignaPolicy IP0324

Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect

This policy governs medical necessity review and coverage criteria for dextromethorphan hydrobromide/quinidine sulfate (Nuedexta) for treatment of pseudobulbar affect for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyDextromethorphan/quinidine (Nuedexta) for pseudobulbar affect

Policy CodePolicy IP0324

Change TypeFormatting/clarity only

Effective Date

Next Review Date

Key ActionObtain prior authorization and document diagnosis of pseudobulbar affect linked to a chronic neurological condition with neurologist involvement.

SourceLink

POLICY UPDATE CHANGES

No criteria changes, minor format updates only.

up to 12 monthsapproval duration

one trialpivotal trial

IP0324policy id

12/01/2024revision date

Coverage Criteria for Dextromethorphan/Quinidine (Nuedexta)

Initial Medical Necessity

Covered when ALL of the following are met

Pseudobulbar Affect diagnosis and prescriber: Individual meets BOTH of the following criteria (A and B): A. Documented diagnosis of pseudobulbar affect associated with a chronic neurological condition (examples include amyotrophic lateral sclerosis, multiple sclerosis, stroke, dementia, traumatic brain injury). B. Medication is prescribed by, or in consultation with, a neurologist.

Examples of chronic neurological conditions are provided in policy.

Reauthorization / Continuation

Continuation covered when ALL of the following are met

Reauthorization: Continuation of dextromethorphan hydrobromide and quinidine sulfate (Nuedexta) is considered medically necessary when the initial medical necessity criteria are met AND there is documentation of beneficial response.

Beneficial response must be documented in the clinical record.

Policy Summary

PayerCigna

PolicyDextromethorphan/quinidine (Nuedexta) for pseudobulbar affect

Policy CodePolicy IP0324

Change TypeFormatting/clarity only

Effective Date

Next Review Date

Key ActionObtain prior authorization and document diagnosis of pseudobulbar affect linked to a chronic neurological condition with neurologist involvement.

SourceLink

On This Page

The following uses of dextromethorphan/quinidine (Nuedexta) are considered experimental, investigational, or unproven and are not covered: heroin detoxification; levodopa‑induced dyskinesia in Parkinson’s disease; neuropathic pain; psychosis‑related aggression; and treatment‑resistant depression. The policy notes that available studies for these indications are limited, often used different DM/quinidine formulations or doses than Nuedexta capsules, and that additional, larger or longer-duration trials are needed to define the drug’s role in these conditions.

Specifically, published data in heroin detoxification are limited and used a formulation/dose not achievable with Nuedexta capsules with no demonstrated benefit versus placebo. A single pilot study suggested benefit for levodopa‑induced dyskinesia but requires larger, longer studies for confirmation. Evidence for neuropathic pain includes small or formulation‑different studies with mixed results and requires more data to establish a role. Case series support potential use for psychosis‑related aggression but are insufficient to establish effectiveness. A small Phase II open‑label study suggested preliminary efficacy for treatment‑resistant depression with a dosing regimen not replicable with Nuedexta capsules; further data are needed.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for dextromethorphan hydrobromide and quinidine sulfate (Nuedexta). Approvals (initial and reauthorization) may be granted for up to 12 months.

Initial approval duration: up to 12 months
Reauthorization approval duration: up to 12 months

Note

Provider Action Summary

Providers must ensure the prescriber is a neurologist or that treatment is provided in consultation with a neurologist. For continuation, document a beneficial clinical response to therapy.

Prescriber: neurologist or documented neurologist consultation
Reauthorization: documentation of beneficial response required

Documentation Required

Required Documentation

Document the diagnosis linking PBA (pseudobulbar affect) to a chronic neurologic condition, the prescriber's specialty or consultation notes with a neurologist, and evidence of benefit for reauthorization.

Diagnosis documentation: PBA associated with a chronic neurologic condition (e.g., ALS, MS, stroke, dementia, TBI)
Prescriber qualification: medication prescribed by or in consultation with a neurologist; include consultation notes if applicable
Reauthorization documentation: clinical notes demonstrating beneficial response to therapy
Other: dosage, frequency, duration, and site of care information as clinically appropriate

Denial Risk

Primary Denial Triggers

Coverage may be denied if required documentation or provider qualifications are missing. Common denial triggers are listed below—confirm all documentation before submission.

Lack of documented diagnosis of pseudobulbar affect linked to a chronic neurologic condition
Absence of prescribing clinician who is a neurologist and no documented neurologist consultation
Insufficient documentation of beneficial response for reauthorization
Incomplete clinical information on dosage, frequency, duration, or site of care

Background

Pseudobulbar affect (PBA) is a neurologic disorder characterized by involuntary, uncontrollable outbursts of laughing and/or crying that are incongruent with or disproportionate to the patient’s underlying emotional state. PBA most often occurs in the setting of an underlying central nervous system disorder and has been described in conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, dementia, and traumatic brain injury.

Clinical management aims to reduce the frequency and severity of PBA attacks; Nuedexta (dextromethorphan/quinidine) is FDA‑indicated for PBA and has demonstrated efficacy in trials that included patients with ALS and MS and other neurologic diagnoses. Treatment goals include symptomatic reduction in attack frequency and periodic reassessment of need because PBA severity may change over time.

OpenPayer

Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect

Coverage Criteria for Dextromethorphan/Quinidine (Nuedexta)

Provider Actions, Prior Authorization, and Documentation

Background

Definitions

Revision History